(NASDAQ: CBIO) today announced that it has signed a.

.

The intention of the Company’s Board of Directors (the “Board”) is to maximize the size. .

17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc.

.

. . The Company is exploring several strategic alternatives to monetize the Company’s legacy assets and is focused on distributing its available cash, after paying or reserving for its.

17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc.

. , Feb. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to assist the Company in exploring strategic alternatives.

. Alternative catalysts based on ionic liquids have shown some promise in this area,.

.

.

. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc.

. .

D.
Hydrogen evolution reaction (HER) is a topic of great interest due to its efficient hydrogen production properties, which can address the increasing demand for.
.

Sep 27, 2019, 13:47 ET.

.

. The intention of the Company’s Board of Directors (the “Board”) is to maximize the size. .

. PDF Version. | Learn more about Yan Mei Chan, Ph. . Apr 2022 - Present1 year 2 months. , June 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc.

.

Aug 1, 2022 · The Board initiated a comprehensive review of strategic alternatives, which resulted in the monetization of a portion of the Company’s product portfolio for significant value. .

.

.

.

<strong>Catalyst Biosciences Sells Complement Portfolio for $60 Million.

Biogen has.